Stockscreener 앱 받기
366.00
0.75%
2.73
시간 외 거래:
366.00
전일 마감가:
$363.27
열려 있는:
$363.31
하루 거래량:
480.21K
Relative Volume:
0.92
시가총액:
$25.76B
수익:
$3.22B
순이익/손실:
$542.70M
주가수익비율:
48.93
EPS:
7.4805
순현금흐름:
$458.00M
1주 성능:
+0.28%
1개월 성능:
+8.62%
6개월 성능:
+41.56%
1년 성능:
+38.86%
1일 변동 폭
$362.18
$370.20
1주일 범위
$359.49
$381.16
52주 변동 폭
$223.83
$386.00
West Pharmaceutical Services Inc Stock (WST) Company Profile
명칭
West Pharmaceutical Services Inc
전화
(610) 594-2900
주소
530 HERMAN O. WEST DRIVE, EXTON, PA
Compare WST vs ISRG, BDX, RMD, MDLN, ALC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
WST
West Pharmaceutical Services Inc
|
366.00 | 25.76B | 3.22B | 542.70M | 458.00M | 7.4805 |
ISRG
Intuitive Surgical Inc
|
423.96 | 149.78B | 11.03B | 3.16B | 3.22B | 8.7251 |
BDX
Becton Dickinson Co
|
183.75 | 50.05B | 21.37B | 1.41B | 3.07B | 3.9437 |
RMD
Resmed Inc
|
230.05 | 32.35B | 5.54B | 1.52B | 1.74B | 10.37 |
MDLN
Medline Inc
|
36.26 | 31.81B | 29.14B | 1.07B | 1.05B | 1.1956 |
ALC
Alcon Inc
|
64.11 | 30.99B | 10.63B | 819.00M | 1.59B | 1.6577 |
West Pharmaceutical Services Inc Stock (WST) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-09-22 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2026-09-09 | 재개 | UBS | Buy |
| 2026-07-13 | 개시 | BNP Paribas Exane | Outperform |
| 2026-06-09 | 업그레이드 | Barclays | Equal Weight → Overweight |
| 2026-06-02 | 재개 | Wolfe Research | Outperform |
| 2025-12-02 | 개시 | Morgan Stanley | Equal-Weight |
| 2025-09-15 | 개시 | Rothschild & Co Redburn | Buy |
| 2025-06-24 | 개시 | Barclays | Equal Weight |
| 2025-03-18 | 개시 | Evercore ISI | Outperform |
| 2025-02-14 | 업그레이드 | Deutsche Bank | Hold → Buy |
| 2025-01-08 | 개시 | Citigroup | Buy |
| 2024-12-13 | 개시 | Wolfe Research | Peer Perform |
| 2024-12-12 | 업그레이드 | UBS | Neutral → Buy |
| 2024-02-07 | 업그레이드 | Jefferies | Hold → Buy |
| 2023-06-16 | 업그레이드 | BofA Securities | Neutral → Buy |
| 2023-04-11 | 업그레이드 | Stephens | Equal-Weight → Overweight |
| 2022-12-14 | 개시 | Deutsche Bank | Hold |
| 2022-11-30 | 개시 | UBS | Neutral |
| 2022-10-28 | 다운그레이드 | BofA Securities | Buy → Neutral |
| 2020-11-10 | 개시 | KeyBanc Capital Markets | Overweight |
| 2020-10-14 | 개시 | Stephens | Equal-Weight |
| 2020-07-21 | 업그레이드 | BofA Securities | Neutral → Buy |
| 2020-04-24 | 업그레이드 | BofA/Merrill | Underperform → Neutral |
| 2019-12-12 | 다운그레이드 | BofA/Merrill | Neutral → Underperform |
| 2019-07-26 | 업그레이드 | BofA/Merrill | Underperform → Neutral |
| 2019-05-01 | 다운그레이드 | Jefferies | Buy → Hold |
| 2019-04-23 | 개시 | William Blair | Outperform |
| 2018-04-25 | 다운그레이드 | BofA/Merrill | Neutral → Underperform |
| 2018-01-24 | 개시 | Goldman | Neutral |
| 2017-10-17 | 다운그레이드 | BofA/Merrill | Buy → Neutral |
| 2017-10-03 | 개시 | Stephens | Equal-Weight |
| 2017-09-15 | 업그레이드 | Jefferies | Hold → Buy |
| 2016-10-28 | 업그레이드 | Wells Fargo | Market Perform → Outperform |
| 2016-09-21 | 다운그레이드 | Wells Fargo | Outperform → Market Perform |
| 2016-03-22 | 개시 | Wells Fargo | Outperform |
| 2010-05-14 | 재확인 | UBS | Neutral |
| 2010-02-23 | 개시 | Jefferies & Co | Buy |
| 2008-12-19 | 개시 | UBS | Neutral |
모두보기
West Pharmaceutical Services Inc 주식(WST)의 최신 뉴스
ANGO Q1 Earnings Beat Estimates on Med Tech Growth, Revenues Up Y/Y - Zacks Investment Research
Reasons to Hold Veeva Systems Stock in Your Portfolio for Now - Zacks Investment Research
Smith+Nephew Launches CARTIHEAL Implant Across Key European Markets - Zacks Investment Research
Here's Why You Should Retain WAT Stock in Your Portfolio for Now - Zacks Investment Research
Reasons to Retain Fresenius Medical Stock in Your Portfolio for Now - Zacks Investment Research
BDX Expands U.S. Manufacturing With $19B Healthcare Investment - Zacks Investment Research
Reasons to Hold HealthEquity Stock in Your Portfolio for Now - Zacks Investment Research
Veeva's DQS Scales Data Automation Across 1,000+ Clinical Studies - Zacks Investment Research
PCR Packaging For Pharma And Otc Market 7.2% CAGR to 2035 on ESG MandatesNews and Statistics - IndexBox
GE HealthCare Expands U.S. PET Radiopharma Reach With SOFIE Deal - TradingView
Reasons to Retain Cardinal Health Stock in Your Portfolio for Now - Zacks Investment Research
Reasons to Retain Cardinal Health Stock in Your Portfolio for Now - TradingView
Barclays Raises West Pharmaceutical Services Price Target to $440 From $400, Maintains Overweight Rating - marketscreener.com
West Pharmaceutical Services Highlights Leadership & Expertise - Contract Pharma
Is West Pharmaceutical Services Inc (WST) Overvalued After 3.2% - GuruFocus
West Pharmaceutical Services Inc. stock outperforms competitors on strong trading day - MarketWatch
Reasons to Retain Doximity Stock in Your Portfolio for Now - Zacks Investment Research
What to Expect From West Pharmaceutical Services' Next Quarterly Earnings Report - Yahoo Finance
What to Expect From West Pharmaceutical Services' Next Quarterly Earnings Report - inkl
West to Highlight Industry Leadership in Packaging and Containment at CPHI Worldwide - PR Newswire
Patient choice and drug-development risks are on the agenda for West's Milan talks - Stock Titan
A director receives 44 units payable in shares at West Pharmaceutical (WST), bringing her balance to 350.87. - Stock Titan
West Pharmaceutical Services Inc. stock outperforms competitors despite losses on the day - MarketWatch
Drug Development Inputs & Services Stocks Q2 Highlights: West Pharmaceutical Services (NYSE:WST) - Yahoo Finance
West Pharmaceutical Services (NYSE:WST) Stock Forecast & Analyst Predictions - Simply Wall Street
West Pharmaceutical Services, I (WST) Stock Forecasts - Yahoo Finance
West Pharmaceutical Services stock reports 13.80 percent revenue growth - AD HOC NEWS
Smith+Nephew Launches EVOS PELVIC System to Advance Trauma Care - Zacks Investment Research
West Pharmaceutical Services stock attracts analyst coverage - AD HOC NEWS
West Pharmaceutical stock enters earnings watch with USD 382.00 target - AD HOC NEWS
West Pharmaceutical Services Inc. stock outperforms competitors on strong trading day - MarketWatch
West Pharmaceutical Services Inc. stock outperforms competitors on strong trading day - MarketWatch
What Comes Next for West Pharmaceutical Services (NYSE:WST)? - kalkinemedia.com
West Pharmaceutical Services stock gains after target rises - ad-hoc-news.de
West Pharmaceutical Services Inc. stock outperforms competitors on strong trading day - MarketWatch
Veeva Unveils Falcon Router to Streamline Biopharma Case Routing - Zacks Investment Research
West Pharmaceutical Services Inc. stock outperforms competitors on strong trading day - MarketWatch
West Pharmaceutical Poised to See EPS Upside to Current 2027 Wall Street Estimates, Morgan Stanley Says - marketscreener.com
West Pharmaceutical Poised to See EPS Upside to Current 2027 Wall Street Estimates, Morgan Stanley Says - Yahoo Finance
West Pharmaceutical Services stock holds near its yearly range - AD HOC NEWS
Morgan Stanley Upgrades West Pharmaceutical Services to Overweight From Equalweight, Adjusts PT to $400 From $365 - Yahoo Finance
Reasons to Hold Hinge Health Stock in Your Portfolio for Now - Zacks Investment Research
West Pharmaceutical Services (WST) Stock Analysis: A Healthcare Powerhouse with 11.89% Potential Upside - DirectorsTalk Interviews
What Is Drawing Attention To West Pharmaceutical Services (WST)? - Yahoo Finance
Two global health firms plan layoffs in metro Phoenix - The Business Journals
West Pharmaceutical Services Inc. stock underperforms Friday when compared to competitors - MarketWatch
Reasons to Add West Pharmaceutical Stock to Your Portfolio Now - Your Wyoming Link
Reasons to Add West Pharmaceutical Stock to Your Portfolio Now - Yahoo Finance
West Pharma to cut 98 jobs as SmartDose production winds down in Arizona - Plastics News
Is West Pharmaceutical Services Stock Outperforming the Nasdaq? - Yahoo Finance
West Pharmaceutical Services Inc (WST) 재무 분석
매출
순이익
현금흐름
주당 순 이익
West Pharmaceutical Services Inc 주식 (WST) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Favorite Annette F | Sr. VP & Chief HR Officer |
Sep 15 '26 |
Sale |
365.00 |
2,524 |
921,260 |
21,818 |
| Favorite Annette F | Sr. VP & Chief HR Officer |
Sep 14 '26 |
Sale |
355.00 |
2,500 |
887,500 |
21,818 |
| Favorite Annette F | Sr. VP & Chief HR Officer |
Sep 11 '26 |
Sale |
345.00 |
2,500 |
862,500 |
21,818 |
| Favorite Annette F | Sr. VP & Chief HR Officer |
Sep 11 '26 |
Option Exercise |
89.64 |
2,500 |
224,100 |
24,318 |
| Favorite Annette F | Sr. VP & Chief HR Officer |
Sep 11 '26 |
Option Exercise |
89.64 |
2,500 |
224,100 |
24,318 |
| Favorite Annette F | Sr. VP & Chief HR Officer |
Sep 08 '26 |
Option Exercise |
85.37 |
8,135 |
694,453 |
19,663 |
| Favorite Annette F | Sr. VP & Chief HR Officer |
Sep 08 '26 |
Sale |
340.81 |
8,135 |
2,772,489 |
16,845 |
| Hofmann Thomas W | Director |
May 07 '26 |
Proposed Sale |
322.12 |
3,384 |
1,090,051 |
0 |
| Winters Chad | VP, Chief Accounting Officer |
Apr 27 '26 |
Sale |
300.67 |
896 |
269,399 |
1,523 |
| Winters Chad | VP, Chief Accounting Officer |
Apr 27 '26 |
Option Exercise |
173.22 |
896 |
155,205 |
2,419 |
1.55%
자본화:
|
볼륨(24시간):